Created at	Source	Raw Value	Validated value
Aug. 23, 2021, 7 p.m.	usa	Phase I clinical trial：The incidence of adverse reactions (ARs) .;Phase II clinical trial：The geometric mean titer(GMT) of specific antibody.;Phase II clinical trial：The geometric mean titer(GMT) of specific antibody.;Phase II clinical trial：The incidence of adverse reactions (ARs) .	Phase I clinical trial：The incidence of adverse reactions (ARs) .;Phase II clinical trial：The geometric mean titer(GMT) of specific antibody.;Phase II clinical trial：The geometric mean titer(GMT) of specific antibody.;Phase II clinical trial：The incidence of adverse reactions (ARs) .